@article{3bb5b910ab0842eb968af09d933aa649,
title = "Kidney-Related Research in the United States: A Position Statement From the National Kidney Foundation and the American Society of Nephrology",
abstract = "Kidney disease is an important US public health problem because it affects over 37 million Americans, and Medicare expenditures for patients with chronic kidney disease now alone exceed $130 billion annually. Kidney disease is characterized by strong racial, ethnic, and socioeconomic disparities, and reducing kidney disease incidence will positively impact US health disparities. Due to the aging of the US population and an unabated obesity epidemic, the number of patients receiving treatment for kidney failure is anticipated to increase, which will escalate kidney disease health expenditures. The historical and current investment in kidney-related research via the National Institute of Diabetes and Digestive and Kidney Diseases has severely lagged behind ongoing expenditures for kidney disease care. Increasing research investment will identify, develop, and increase implementation of interventions to slow kidney disease progression, reduce incidence of kidney failure, enhance survival, and improve quality of life. This perspective states the urgent reasons why increasing investment in kidney-related research is important for US public health. The National Kidney Foundation and the American Society of Nephrology are working together to advocate for increased funding for the National Institute of Diabetes and Digestive and Kidney Diseases. The long-term goal is to reduce the burden of kidney disease in the US population and improve the quality of life of patients living with kidney disease.",
keywords = "Kidney disease, end-stage kidney disease (ESKD), health care policy, health disparities, population health, public health, race disparities, research, research funding",
author = "Ryan Murray and Troy Zimmerman and Anupam Agarwal and Palevsky, {Paul M.} and Susan Quaggin and Rosas, {Sylvia E.} and Holly Kramer",
note = "Funding Information: Mr Murray is employed by the ASN as Senior Policy Specialist. Mr Zimmerman is employed by the NKF as Vice President, Government Relations. Dr Agarwal is past president of the ASN; serves as a consultant for Dynamed; and is on the advisory boards of Goldilocks Therapeutics, Reata, Akebia, Alpha Young, and Angion for work outside the scope of this article. Dr Palevsky is president of the NKF and receives research funding from NIDDK and the Department of Veterans Affairs Office of Research and Development. Dr Quaggin is president of the ASN and receives research funding from the NIDDK. Dr Rosas is president-elect of the NKF; receives research funding from NIDDK, Bayer Healthcare, and Astra Zeneca; and participates in scientific advisory boards for the NKF, Reata, Relypsa, and Bayer. Dr Kramer is past president of the NKF; serves as a consultant for Bayer Pharmaceuticals; reports receipt of honoraria from Nutrica and PeaPod; and receives research funding from NIDDK. Funding Information: Ryan Murray, BA, Troy Zimmerman, BA, Anupam Agarwal, MD, Paul M. Palevsky, MD, Susan Quaggin, MD, Sylvia E. Rosas, MD, MSCE, and Holly Kramer, MD, MPH. This work was funded by the NKF. Mr Murray is employed by the ASN as Senior Policy Specialist. Mr Zimmerman is employed by the NKF as Vice President, Government Relations. Dr Agarwal is past president of the ASN; serves as a consultant for Dynamed; and is on the advisory boards of Goldilocks Therapeutics, Reata, Akebia, Alpha Young, and Angion for work outside the scope of this article. Dr Palevsky is president of the NKF and receives research funding from NIDDK and the Department of Veterans Affairs Office of Research and Development. Dr Quaggin is president of the ASN and receives research funding from the NIDDK. Dr Rosas is president-elect of the NKF; receives research funding from NIDDK, Bayer Healthcare, and Astra Zeneca; and participates in scientific advisory boards for the NKF, Reata, Relypsa, and Bayer. Dr Kramer is past president of the NKF; serves as a consultant for Bayer Pharmaceuticals; reports receipt of honoraria from Nutrica and PeaPod; and receives research funding from NIDDK. The authors thank Tom Mattix for assistance with figure preparation. Received April 21, 2021, following review and approval by the NKF Scientific Advisory Board (membership listed at https://www.kidney.org/about/sab) and the NKF Executive Committee (listed at https://www.kidney.org/about/board) and by the leadership of the ASN. Accepted April 23, 2021, after editorial review by a Deputy Editor. Publisher Copyright: {\textcopyright} 2021",
year = "2021",
month = aug,
doi = "10.1053/j.ajkd.2021.04.006",
language = "English (US)",
volume = "78",
pages = "161--167",
journal = "American Journal of Kidney Diseases",
issn = "0272-6386",
publisher = "W.B. Saunders Ltd",
number = "2",
}
